Provention Bio’s Earnings Outlook
Provention Bio (NASDAQ:PRVB) is set to give its latest quarterly earnings report on Thursday, 2023-03-16. Here’s what investors…
HC Wainwright & Co. Downgrades Provention Bio to Neutral, Raises Price Target to $25
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Provention Bio (NASDAQ:PRVB) from Buy to Neutral and raises the price target from $16 to $25.
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Jefferies Downgrades Provention Bio to Hold, Announces $25 Price Target
Jefferies analyst Chris Howerton downgrades Provention Bio (NASDAQ:PRVB) from Buy to Hold and announces $25 price target.
Nasdaq Up 150 Points; Gold Rises Over 2%
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 150 points on Monday.
The Dow traded up 0.59% to 32,096.68 while the NASDAQ rose 1.35% to 11,288.8. The S&P 500, also rose, gaining, 0.78% 3,891.75.
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash.
Provention Bio’s $2.9B Acquisition – A Strategic Fit For Sanofi
Sanofi SA (NASDAQ:SNY) has agreed to acquire Provention Bio Inc (NASDAQ:PRVB) for $25.00 per share in cash, representing an equity value of approximately…
US Stocks Mostly Higher; Dow Rises 75 Points
U.S. stocks traded mostly higher this morning, with the Dow Jones gaining around 75 points on Monday.
Following the market opening Monday, the Dow traded up 0.24% to 31,986.55 while the NASDAQ rose 0.24% to 11,165.62. The S&P 500, meanwhile, fell, dropping, 0.03% to 3,860.50.
Chardan Capital Maintains Buy on Provention Bio, Lowers Price Target to $25
Chardan Capital analyst Geulah Livshits maintains Provention Bio (NASDAQ:PRVB) with a Buy and lowers the price target from $30 to $25.
Why Prevention Bio Stock Is Rocketing Past 52-Week Highs Today
Provention Bio Inc (NASDAQ: PRVB) shares are rocketing higher Monday after Sanofi (NASDAQ: SNY) announced plans to acquire the biopharmaceutical company.</